348 related articles for article (PubMed ID: 16919374)
1. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture.
Liu CC; Lian WC; Butler M; Wu SC
Vaccine; 2007 Jan; 25(1):19-24. PubMed ID: 16919374
[TBL] [Abstract][Full Text] [Related]
2. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
Wu SC; Liu CC; Lian WC
Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
4. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
Rourou S; van der Ark A; van der Velden T; Kallel H
Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
[TBL] [Abstract][Full Text] [Related]
5. Suspension-Vero cell cultures as a platform for viral vaccine production.
Paillet C; Forno G; Kratje R; Etcheverrigaray M
Vaccine; 2009 Oct; 27(46):6464-7. PubMed ID: 19559123
[TBL] [Abstract][Full Text] [Related]
6. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.
Wu TC; Wang YF; Lee YP; Wang JR; Liu CC; Wang SM; Lei HY; Su IJ; Yu CK
J Virol; 2007 Oct; 81(19):10310-5. PubMed ID: 17626076
[TBL] [Abstract][Full Text] [Related]
7. Vero-cell rabies vaccine produced using serum-free medium.
Frazatti-Gallina NM; Mourão-Fuches RM; Paoli RL; Silva ML; Miyaki C; Valentini EJ; Raw I; Higashi HG
Vaccine; 2004 Dec; 23(4):511-7. PubMed ID: 15530700
[TBL] [Abstract][Full Text] [Related]
8. Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor.
Toriniwa H; Komiya T
Biologicals; 2007 Oct; 35(4):221-6. PubMed ID: 17400474
[TBL] [Abstract][Full Text] [Related]
9. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
[TBL] [Abstract][Full Text] [Related]
10. Production of yellow fever virus in microcarrier-based Vero cell cultures.
Souza MC; Freire MS; Schulze EA; Gaspar LP; Castilho LR
Vaccine; 2009 Oct; 27(46):6420-3. PubMed ID: 19559120
[TBL] [Abstract][Full Text] [Related]
11. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
Genzel Y; Fischer M; Reichl U
Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
[TBL] [Abstract][Full Text] [Related]
12. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
13. Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process.
Liu CC; Chang HW; Yang G; Chiang JR; Chow YH; Sai IH; Chang JY; Lin SC; Sia C; Hsiao CH; Chou AH; Chong P
J Virol Methods; 2011 Sep; 176(1-2):60-8. PubMed ID: 21704080
[TBL] [Abstract][Full Text] [Related]
14. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture.
Liu CC; Wu SC; Wu SR; Lin HY; Guo MS; Yung-Chih Hu A; Chow YH; Chiang JR; Shieh DB; Chong P
Vaccine; 2018 May; 36(22):3134-3139. PubMed ID: 28274636
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate.
Lin YC; Wu CN; Shih SR; Ho MS
Vaccine; 2002 Jun; 20(19-20):2485-93. PubMed ID: 12057603
[TBL] [Abstract][Full Text] [Related]
16. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.
Genzel Y; Olmer RM; Schäfer B; Reichl U
Vaccine; 2006 Aug; 24(35-36):6074-87. PubMed ID: 16781022
[TBL] [Abstract][Full Text] [Related]
17. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
[TBL] [Abstract][Full Text] [Related]
18. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
[TBL] [Abstract][Full Text] [Related]
19. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment.
Ch'ng WC; Stanbridge EJ; Ong KC; Wong KT; Yusoff K; Shafee N
J Med Virol; 2011 Oct; 83(10):1783-91. PubMed ID: 21837796
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a mink enteritis vaccine production process in stirred-tank reactor and Wave Bioreactor microcarrier culture in 1-10 L scale.
Hundt B; Best C; Schlawin N; Kassner H; Genzel Y; Reichl U
Vaccine; 2007 May; 25(20):3987-95. PubMed ID: 17391818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
